Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine
Shares of Novavax (NASDAQ:NVAX) fell roughly 30% Wednesday morning after the U.S. FDA put a clinical hold on the new drug application of its COVID-19 and influenza combination vaccine and standalone influenza vaccine candidates,
FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
FDA Puts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Tumbles
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza
Novavax, Inc. (NASDAQ:NVAX) Shares Tumbled on Wednesday Following Clinical Hold on Flu Combination Vaccine
Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years post-vaccination.,Analysts at Jefferies revised their price target for Novavax from $31 to $25 amid increased uncertainty about the
Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines
Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.
FDA halts trial of Novavax COVID-flu combo shot
The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a standalone flu shot, after a participant suffered a serious adverse event, the company said on Wednesday.
Novavax shares sink as US FDA puts trial of combo COVID-flu vaccine on hold
Shares in Novavax (NASDAQ:NVAX) slumped in premarket US trading on Wednesday after the US Food and Drug Administration placed a trial of its experimental COVID-19 and influenza vaccine combination on hold.
bovnews2d
NVAX Unveiled: The Shocking Truth Behind Novavax Inc’s Latest Stock Movements
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...
Zacks.com on MSN2d
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock ...
news.stocktradersdaily2d
Trading (NVAX) With Integrated Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
SchaeffersResearch.com3d
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
Zacks.com on MSN2d
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...